化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

蒋琦; 钱其军

doi:10.3969/j.issn.1006-0111.2015.02.019

化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2015.02.019

蒋琦,
钱其军

东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

基金项目: 国家科技重大专项资助项目(No.2013ZX10002-010-007)

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

摘要: 肿瘤相关免疫抑制性细胞在肿瘤的发生、发展过程中发挥重要的免疫抑制作用,肿瘤的发展和转移常伴有这些细胞的异常聚集。调节性T细胞(regulatory T cells, Treg)和髓系来源的抑制性细胞(myeloid-derived suppressor cells,MDSC)是免疫抑制性细胞网络的主要成分,它们通过直接或间接作用负向调节其他免疫细胞,抑制抗肿瘤的免疫反应。最新研究显示,有些常规化疗药物除可直接杀伤肿瘤细胞外,还可降低Treg和MDSC的数量,抑制其功能,从而增强抗肿瘤免疫功能。因此,将化疗药物作为预处理方案,凭借其免疫调节作用联合后续的过继性细胞免疫治疗可有效增强抗肿瘤免疫应答。化学免疫治疗策略将改变人们对传统化疗抗肿瘤地位的认识,继而更加合理地应用化疗药物。
- 化疗药物 /
- 调节性T细胞 /
- 髓系来源的抑制性细胞 /
- 化学免疫治疗 /
- 免疫抑制性细胞
Abstract: Cancer-induced immunosuppressive cells play an important immunosuppressive role during the tumor development process, and the development and progression of tumors are always accompanied with abnormal accumulation of cancer-induced immunosuppressive cells. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC) are major components of these inhibitory cellular networks, and they can inhibit antitumor immune response through multiple mechanisms. Recent studies have provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, some conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced anti-tumor immunity. Hence, chemotherapeutics, used as a preconditioning regimen and combined with subsequent immunotherapy, can promote anti-tumor immune response. Anticancer chemoimmunotherapy strategy will change the recognization of the role for conventional chemotherapy in anticancer treatment, and it will be helpful to optimize the chemotherapy strategies more reasonably.
- chemotherapeutics /
- regulatory T cell /
- myeloid-derived suppressor cell /
- chemoimmunotherapy /
- cancer-induced immunosuppressive cell

[1]	Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer[J].Clin Genitourin Cancer,2006,5(3),206-211.
[2]	Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion[J]. Nat Rev Immunol,2006,6(10):715-727.
[3]	Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009,9(3):162-174.
[4]	Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy[J]. Nat Rev Cancer,2007,7(11):880-887.
[5]	Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med,2004,10(9):942-949.
[6]	Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol,1995,155(3):1151-1164.
[7]	曾益新,吕有勇,朱明华,等.肿瘤学[M].3版. 北京:人民卫生出版社,2012:281-282.
[8]	North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells[J]. J Exp Med,1982,155(4):1063-1074.
[9]	Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy[J]. Adv Cancer Res,2010,107:1-37.
[10]	Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model[J]. Cancer Res,2009,69(10):4309-4318.
[11]	Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative[J]. Eur J Immunol,2004,34(2):336-344.
[12]	Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity[J]. Cancer Immunol Immunother,2013,62(2):203-216.
[13]	Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy?[J]. Br J Cancer,2009,100(11):1697-1703.
[14]	Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother,2007,56(5):641-648.
[15]	Zhang L,Dermawan K,Jin M,et al.Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J].Clin Immunol,2008,129(2):219-229.
[16]	Liu N, Zheng Y, Zhu Y, et al. Selective impairment of CD4+CD25+Foxp3⁽⁺⁾ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis[J]. Int mmunopharmacol,2011,11(2):212-219.
[17]	Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement[J]. Clin Cancer Res,2008,14(11):3536-3544.
[18]	Reinartz S, Pfisterer J, du Bois A, et al. Suppressive activity rather than frequency of FoxP3⁽⁺⁾ regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment[J]. Hum Immunol,2010,71(1):36-44.
[19]	Banissi C, Ghiringhelli F, Chen L, et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model[J]. Cancer Immunol Immunother,2009,58(10):1627-1634.
[20]	Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25+Foxp3⁽⁺⁾ regulatory T-cells in advanced melanoma patients[J]. J Transl Med,2013,11:135.
[21]	Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients[J]. J Clin Oncol,2005,23(35):8950-8958.
[22]	Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells[J]. Cancer Immunol Immunother,2009,58(7):1033-1045.
[23]	Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer[J]. J Immunol,2009,182(8):4499-4506.
[24]	Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J]. Cancer Res,2010,70(8):3052-3061.
[25]	Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers[J]. Clin Cancer Res,2010,16(18):4583-4594.
[26]	Kodumudi KN, Weber A, Sarnaik AA, et al. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma[J]. J Immunol,2012,189(11):5147-5154.
[27]	Michels T, Shurin GV, Naiditch H, et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner[J]. J Immunotoxicol,2012,9(3):292-300.
[28]	Alizadeh D, Trad M, Hanke NT, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J]. Cancer Res,2014,74(1):104-118.
[29]	Mikysková R, Indrová M, Vlková V, et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment[J]. J Leukoc Biol,2014,95(5):743-753.
[30]	Mikysková R, Indrová M, Pollaková V, et al. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors[J]. J Immunother,2012,35(5):374-384.

[1]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[2]	闻韬, 焦广洋, 赵梦沛, 岳小强, 张凤, 陈万生. 基于UHPLC-Q-TOF/MS结合网络药理学研究柴胡桂枝干姜汤治疗慢性非萎缩性胃炎的物质基础及疗效机制 . 药学实践与服务, 2025, 43(): 1-9. doi: 10.12206/j.issn.2097-2024.202312061
[3]	杨金润, 黎翔, 孙旸. ORM1促肝细胞增殖的作用及其机制探索 . 药学实践与服务, 2025, 43(5): 1-6. doi: 10.12206/j.issn.2097-2024.202410014
[4]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2025, 43(4): 151-155, 173. doi: 10.12206/j.issn.2097-2024.202408045
[5]	赵全公, 王国坤, 徐志云. 虾青素通过激活Nrf2/HO-1通路抑制瓣膜间质细胞钙化 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202412057
[6]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架治疗创伤性脑损伤的研究 . 药学实践与服务, 2025, 43(2): 67-74. doi: 10.12206/j.issn.2097-2024.202406034
[7]	曹奇, 张嘉宝, 王培. 基于无监督自动降维分析与手动圈门联用的骨骼肌髓系细胞多色流式分析方法 . 药学实践与服务, 2025, 43(3): 118-122. doi: 10.12206/j.issn.2097-2024.202404077
[8]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[9]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[10]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[11]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[12]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[13]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[14]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[15]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[16]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[17]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[18]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[19]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[20]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023

点击查看大图

计量

文章访问数: 3628
HTML全文浏览量: 302
PDF下载量: 594
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2015.02.019

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

计量

化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2015.02.019

东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

English Abstract

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

全文HTML

目录

留言板

化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2015.02.019

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

计量

出版历程

化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2015.02.019

东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

English Abstract

Chemotherapeutic targeting of cancer-induced immunosuppressive cells: an update research

Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

全文HTML

目录